| [1] |
Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study [J]. Ann Transl Med, 2020, 8(7): 482.
|
| [2] |
马春光, 叶定伟, 李长岭, 等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析 [J]. 中华外科杂志, 2008, 46(12): 921-925.
|
| [3] |
Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma [J]. Cancer, 2000, 88(12 Suppl): 2989-2994.
|
| [4] |
Adami S. Bisphosphonates in prostate carcinoma [J]. Cancer, 1997, 80(8 Suppl): 1674-1679.
|
| [5] |
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J]. Lancet, 2011, 377(9768): 813-822
|
| [6] |
Gralow JR, Biermann JS, Farooki A, et al. Nccn task force report: bone health in cancer care [J]. J Natl compr Canc Netw, 2013, 11 Suppl 3: S1-50; quiz S51.
|
| [7] |
Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J]. J Natl Cancer Inst, 2004, 96(11): 879-882.
|
| [8] |
Hussain SA, Weston R, Stephenson RN, et al. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation [J]. BJU Int, 2003, 92(7): 690-694.
|
| [9] |
Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden [J]. Eur J Cancer, 2012, 48(11): 1672-1681.
|
| [10] |
Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy [J]. J Urol, 2002, 167(6): 2361-2367.
|
| [11] |
Buehring B, Viswanathan R, Binkley N, et al. Glucocorticoid-induced osteoporosis: an update on effects and management [J]. J Allergy Clin Immunol, 2013, 132(5): 1019-1030.
|
| [12] |
Myint ZW, Momo HD, Otto DE, et al. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis [J]. JAMA Network Open, 2020, 3(11): e2025826
|
| [13] |
Saad F, Ivanescu C, Phung D, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials[J]. Prostate Cancer Prostatic Dis, 2017, 20(1): 110-116.
|
| [14] |
中国抗癌协会癌症康复与姑息治疗专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会. 恶性肿瘤骨转移及骨相关疾病临床诊疗专家共识(2014版)[M]. 北京：北京大学医学出版社, 2014.
|
| [15] |
Bedard G, Wong E. 骨转移手册-医护专业人员版(第二版)[M]. 中南大学出版社, 2018.
|
| [16] |
袁昆, 王国寿. CT、磁共振成像和DR在鉴别良恶性脊柱骨折中的应用价值分析[J]. 中国实用医药, 2020, 15(36): 87-88.
|
| [17] |
Turpin A, Girard E, Baillet C, et al. Imaging for metastasis in prostate cancer: a review of the literature [J]. Front Oncol, 2020, 10: 55.
|
| [18] |
Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer [J]. Eur Urol, 2017, 71(1): 81-92.
|
| [19] |
周长友, 陈久尊, 何家维, 等. 四肢骨转移瘤的影像学分析 [J]. 实用放射学杂志, 2013, 29(11): 1823-1825.
|
| [20] |
Pomykala KL, Czernin J, Grogan TR, et al. Total-Body (68)Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines [J]. J Nucl Med, 2020, 61(3): 405-411.
|
| [21] |
Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer [J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 469-476.
|
| [22] |
Ross RW, Halabi S, Ou SS, et al. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer-a Cancer and Leukemia Group B study [J]. Clin Cancer Res, 2005, 11(22): 8109-8113.
|
| [23] |
Sailer V, Schiffman MH, Kossai M, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine [J]. Cancer, 2018, 124(5): 1008-1015.
|
| [24] |
杨文博, 王强, 杜依青, 等. 雄激素剥夺治疗前列腺癌引起的骨代谢变化 [J]. 临床泌尿外科杂志, 2021, 36(1): 68-71.
|
| [25] |
黄莉, 毛丽妮. 前列腺癌经雄激素剥夺治疗后骨代谢异常和骨折风险的监测评估 [J]. 国际泌尿系统杂志, 2022, 42(3): 462-465.
|
| [26] |
Badri SAME, Salawu A, Brown JE. Bone health in men with prostate cancer: Review article [J]. Curr Osteoporos Rep, 2019, 17(6): 527-537.
|
| [27] |
Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III e3805 chaarted trial [J]. J Clin Oncol, 2018, 36(11): 1080-1087.
|
| [28] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）前列腺癌诊疗指南2022 [M]. 北京：人民卫生出版社, 2022.
|
| [29] |
Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: esmo clinical practice guidelines [J]. Ann Oncol, 2020, 31(12): 1650-1663.
|
| [30] |
中华医学会物理医学与康复学会分会, 中国老年学和老年医学学会骨质疏松康复分会. 原发性骨质疏松症康复干预中国专家共识 [J]. 中华物理医学与康复杂志, 2019, 41(1): 1-7.
|
| [31] |
Zhang X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer [J]. Cancer Commun (Lond), 2019, 39(1): 76.
|
| [32] |
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468.
|
| [33] |
Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance) [J]. J Clin Oncol, 2014, 32(11): 1143-1150.
|
| [34] |
Schaeffer EM, Srinivas S, An Y, et al. NCCN clinical practice guidelines in oncology: prostate cancer（Version 1. 2023）[EB/OL].[2022-9-16]
URL
|
| [35] |
Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial[J]. JAMA, 2017, 317(1): 48-58.
|
| [36] |
Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients [J]. J Oral Maxillofac Surg, 2003, 61(10): 1238-1239.
|
| [37] |
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer [J]. N Engl J Med, 2013, 369(3): 213-223.
|
| [38] |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-psma-617 for metastatic castration-resistant prostate cancer [J]. N Engl J Med, 2021, 385(12): 1091-1103.
|
| [39] |
Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases [J]. J Natl Cancer Inst, 2005, 97(11): 798-804.
|
| [40] |
van de Ven S, van den Bongard D, Pielkenrood B, et al. Patient-reported outcomes of oligometastatic patients after conventional or stereotactic radiation therapy to bone metastases: an analysis of the present cohort [J]. Int J Radiat Oncol Biol Phys, 2020, 107(1): 39-47.
|
| [41] |
Sprave T, Verma V, Förster R, et al. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial [J]. BMC cancer, 2018, 18(1): 859.
|
| [42] |
Sahgal A, Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial [J]. Lancet Oncology, 2021, 22(7): 1023-1033.
|
| [43] |
Nguyen QN, Chun SG, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial [J]. JAMA oncology, 2019, 5(6): 872-878.
|
| [44] |
Gao RW, Olivier KR, Park SS, et al. Single-fraction stereotactic body radiation therapy versus conventionally fractionated radiation therapy for the treatment of prostate cancer bone metastases[J]. Adv Radiat Oncol, 2019, 4(2): 314-322.
|
| [45] |
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase ii trial[J]. J Clin Oncol, 2018, 36(5): 446-453.
|
| [46] |
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial[J]. JAMA oncology, 2020, 6(5): 650-659.
|
| [47] |
Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group [J]. J Clin Oncol, 2011, 29(22): 3072-3077.
|
| [48] |
Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale [J]. J Neurosurg Spine, 2010, 13(3): 324-328.
|
| [49] |
Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures [J]. Clin Orthop Relat Res, 1989, (249): 256-264.
|
| [50] |
Tomita K, Kawahara N, Baba H, et al. Total en bloc spondylectomy. A new surgical technique for primary malignant vertebral tumors [J]. Spine(Phila Pa 1976), 1997, 22(3): 324-333.
|
| [51] |
Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone [J]. J Bone Joint Surg Am, 1978, 60(6): 731-746.
|
| [52] |
Zhang Y, Guo W, Tang X, et al. En bloc resection of pelvic sarcomas with sacral invasion: a classification of surgical approaches and outcomes [J]. Bone Joint J, 2018, 100-b(6): 798-805.
|
| [53] |
Zhu X, Lu J, Xu H, et al. A comparative study between minimally invasive spine surgery and traditional open surgery for patients with spinal metastasis [J]. Spine(Phila Pa 1976), 2021, 46(1): 62-68.
|
| [54] |
Hansen-Algenstaedt N, Kwan MK, Algenstaedt P, et al. Comparison between minimally invasive surgery and conventional open surgery for patients with spinal metastasis: a prospective propensity score-matched study[J]. Spine(Phila Pa 1976), 2017, 42(10): 789-797.
|
| [55] |
Hikata T, Isogai N, Shiono Y, et al. A Retrospective Cohort Study Comparing the Safety and Efficacy of Minimally Invasive Versus Open Surgical Techniques in the Treatment of Spinal Metastases [J]. Clin Spine Surg, 2017, 30(8): E1082-e1087.
|
| [56] |
徐瑞华, 万德森. 临床肿瘤学 [M]. 北京: 科学出版社, 2020.
|